Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/DMT/Health Economics & Reimbursement

DMT for Health Economics & Reimbursement

2 papers and 0 clinical trials exploring dmt as a treatment for health economics & reimbursement.

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
IndicationApproximately 300 million individuals worldwide suffer from depression, with PTSD affecting about 7-8% of the US population at some point in their lives.

Health Economics & Reimbursement

Psychedelic-assisted therapies are gaining traction in the health economics domain, with promising findings regarding their efficacy in treating mental health disorders. As the FDA considers approval for compounds like MDMA and psilocybin, the economic implications, including reimbursement models, are increasingly relevant to healthcare systems worldwide.

Full Health Economics & Reimbursement profile

Academic Research

2 papers
Paywallindividual

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression

This open-label fixed-order dose-escalation trial (n=14) evaluated inhaled DMT (15mg & 60mg) for treatment-resistant depression (TRD) for the first time. Results showed rapid and sustained antidepressant effects with a 21-point reduction on the Montgomery-Asberg Depression Rating Scale by day 7 (p<0.001), an 86% response rate, and a 57% remission rate lasting up to 3 months, with significant decreases in suicidal ideation (SI).

Published
April 22, 2025
Journal
Neuropsychopharmacology
Authors
Falchi-Carvalho, M., Palhano-Fontes, F., Wießner, I., Barros, H., Bolcont, R., Laborde, S., Silva, S. R. B., Montanini, D., Barbosa, D. C., Teixeira, E., Florence-Vilela, R., Almeida, R., Macedo, R. K. A., Arichelle, F., Pantrigo, E. J., Costa-Macedo, J. V., da Cruz Nunes, J. A., Araújo, D. B., de Araujo Costa Neto, L. A., Nunes Ferreira, L. F., Dantas Correa, L., da Costa Bezerra, R. B., Arcoverde, E., Galvão-Coelho, N. L.
Open Accessindividual

Effects of DMT on mental health outcomes in healthy volunteers

In healthy volunteers, intravenous DMT produced significant reductions in depressive symptoms one to two weeks after administration in both placebo-controlled and prospective samples, with trait neuroticism reduced only in the placebo-controlled group and symptom change correlated with the intensity of acute "oceanic boundlessness" peak experiences. The authors suggest IV DMT’s short, controllable action may alleviate depressive symptomatology via induced peak experiences and warrants further clinical investigation.

Published
February 7, 2024
Journal
Scientific Reports
Authors
Timmermann, C., Zeifman, R. J., Erritzoe, D., Nutt, D. J., Carhart-Harris, R. L.

Clinical Trials

0 trials

No clinical trials have been tagged with both DMT and Health Economics & Reimbursement yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all DMT papers Search all Health Economics & Reimbursement trials Full DMT profile Full Health Economics & Reimbursement profile